After a challenging CY2021, growth in chronic therapies continues to recover. Domestic companies grew 10 per cent yoy compared to 8 per cent yoy growth for MNC companies in Aug 2022. IPM growth was bolstered by impressive yoy performance across most therapies, led by gastro-intestinal, gynae and pai
Read More